Reenaers Catherine, Bossuyt Peter, Hindryckx Pieter, Vanpoucke Hilde, Cremer Anneline, Baert Filip
Department of Gastroenterology, CHU Sart Tilman, Liège, Belgium.
Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
United European Gastroenterol J. 2018 Oct;6(8):1117-1125. doi: 10.1177/2050640618784046. Epub 2018 Jun 20.
Despite many publications regarding the role of faecal calprotectin (FC) in inflammatory bowel disease (IBD), clear recommendations for its use in clinical practice are currently lacking in the literature.
The aim of this article is to provide practical guidance for clinicians for the use of FC in the detection and management of patients with IBD.
All relevant publications were analysed and practical statements were proposed based on a Delphi consensus approach.
Different commercial assays have been developed but international standardisation is lacking. FC can help in the diagnosis process of IBD. In IBD, FC can predict response to therapy, detect subclinical inflammation and help to drive treatment decisions to achieve better endoscopic and clinical outcomes. After Crohn's surgery FC can identify patients with early endoscopic recurrence.
Although major therapeutic changes should not be based on FC alone, FC is a valuable tool to optimise the care for IBD patients.
尽管有许多关于粪便钙卫蛋白（FC）在炎症性肠病（IBD）中作用的出版物，但目前文献中缺乏关于其在临床实践中使用的明确建议。
本文旨在为临床医生在IBD患者的检测和管理中使用FC提供实用指导。
分析所有相关出版物，并基于德尔菲共识方法提出实用声明。
已开发出不同的商业检测方法，但缺乏国际标准化。FC有助于IBD的诊断过程。在IBD中，FC可以预测治疗反应，检测亚临床炎症，并有助于推动治疗决策以实现更好的内镜和临床结果。克罗恩病手术后，FC可以识别早期内镜复发的患者。
虽然主要的治疗改变不应仅基于FC，但FC是优化IBD患者护理的有价值工具。
